Rapid Micro Biosystems Q2 2026 revenue up 11% to $8.1M; gross margin record 15%

RAPID MICRO BIOSYSTEMS, INC.

Q2 2026 total revenue $8.1M, +10.9% YoY; product $5.3M, service $2.8M, recurring $5.0M (+14.3%).
Gross margin 15.0% vs 3.8% YoY; net loss $12.9M ($0.27/share) vs $11.9M loss ($0.27/share) prior year.
Placed 4 Growth Direct systems, completed 9 validations; 200th system placed globally.
Reaffirms FY2026 revenue guidance $37-41M, 30-38 placements, ~20% gross margin; raises validation guidance to at least 27.
Cash, equivalents and short-term investments ~$20M as of June 30, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.